MSLN and colorectal adenocarcinoma: A comparison of MSLN immunostaining with pT, pN, and histological grade in 1619 colorectal adenocarcinomas, 1072 invasive breast carcinomas of no special type, 386 serous carcinomas of the ovary, 174 lung adenocarcinomas, 757 clear cell renal cell carcinomas, and 171 endometrioid endometrial, in 373 gastric, and in 925 bladder carcinomas revealed only a statistically significant association between MSLN immunostaining and pT stage, as well as pN status in colorectal cancer (p < 0.0001 each, Table 2).